Barker, JM, Goehrig SH, Barriga K, et al. Clinical characteristics of children
diagnosed with type 1 diabetes through intensive screening and follow-up.
Diabetes Care, 2004. 27(6): 1399-404.
Pitkäniemi J, Onkamo P, Tuomilehto J, Arjas E. Increasing incidence of
Type 1 diabetes--role for genes? BMC Genet. 2004 2; 5: 5.
Basta G, Montanucci P, Luca G, et al. Long-term metabolic and
immunological follow-up of nonimmunosuppressed patients with type 1 diabetes
treated with microencapsulated islet allografts: Four cases. Diabetes Care. 2011
Nov; 34(11): 2406-9. doi: 10.2337/dc11-0731.
Luca G, Fallarino F, Calvitti M, et al. Xenograf of microencapsulated Sertoli
cells reverses T1DM in NOD mice by inducing neogenesis of beta-cells.
Transplantation. 2011; 90(12): 1352-7.
Mital P, Kaur G, Dufour J. Immunoprotective Sertoli cells: Making
allogeneic and xenogeneic transplantation feasible. Reproduction. 2010; 139(3):
495-504. doi: 10.1530/REP-09-0384.
Zhao Y, Jiang Z, Zhao T, et al. Reversal of type 1 diabetes via islet β cell
regeneration following immune modulation by cord blood-derived multipotent
stem cells. BMC Med. 2012 Jan 10; 10: 3. doi: 10.1186/1741-7015-10-3.
Hu J, Wang Y, Gong H, et al. Long term effect and safety of Wharton’s jelly-
derived mesenchymal stem cells on type 2 diabetes. Exp Ther Med. 2016 Sep;
12(3): 1857-1866. Epub 2016 Jul 26.
Carlsson PO, Schwarcz E, Korsgren O, Le Blanc K. Preserved β-cell
function in type 1 diabetes by mesenchymal stromal cells. Diabetes. 2015 Feb;
64(2): 587-92. doi: 10.2337/db14-0656.
Bhansali A, Upreti V, Khandelwal N, et al. Efficacy of autologous bone
marrow-derived stem cell transplantation in patients with type 2 diabetes
mellitus.
Stem
Cells
Dev.
2009
Dec;
18(10):1407-16.
doi:
10.1089/scd.2009.0164.
Skyler JS, Fonseca VA, Segal KR, Rosenstock J. Allogeneic mesenchymal
precursor cells in type 2 diabetes: A Randomized, placebo-controlled, dose-
